Ocugen shares rise 12.58% premarket after securing $22.5M funding via 15M share offering to extend financial runway through late 2026.

Ocugen surged 12.58% in premarket trading following the announcement of a $22.5 million equity offering led by institutional investors, including RTW Investments, which extended its financial runway through late 2026. The capital raise, priced at $1.50 per share, was accompanied by positive interim Phase 2 clinical data for its lead gene therapy candidate, OCU410, showing a 46–54% reduction in lesion growth for geographic atrophy. The combination of secured funding and favorable trial results alleviated short-term liquidity concerns while reinforcing confidence in the company’s pipeline advancement, directly supporting the premarket rally.